J Korean Neurol Assoc.  2017 Feb;35(1):26-29. 10.17340/jkna.2017.1.5.

Remission after Rituximab Therapy in Refractory Myasthenia Gravis

Affiliations
  • 1Department of Neurology, Dongguk University College of Medicine, Gyeongju, Korea.
  • 2Department of Neurology, Kyungpook National University School of Medicine, Daegu, Korea. jinforeva@gmail.com

Abstract

Myasthenia gravis (MG) is estimated to be refractory in approximately 10% of patients with generalized MG. A 35-year-old man was diagnosed as generalized MG with thymoma. Despite aggressive immunotherapies, his myasthenic symptoms relapsed five times within one year. We therefore administered rituximab for treating the refractory MG, and this resulted in remission. There are few reports on treating MG with rituximab, but this case suggests that rituximab can be an effective treatment option for refractory MG.

Keyword

Refractory myasthenia gravis; Immuthotherapy; Rituximab

MeSH Terms

Adult
Humans
Immunotherapy
Myasthenia Gravis*
Rituximab*
Thymoma
Rituximab
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error